Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus immunotherapy with or without probiotics in small cell lung cancer
ChiCTR2200067200Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bacillus licheniformis, Medilac-S and bifidobacterium triple viable in small cell lung cancer (SCLC) (4 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Overall survival. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
bacillus licheniformisMedilac-Sbifidobacterium triple viable
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200067200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067200.